BACKGROUND: The entrance of naive T cells into lymph nodes (LNs) is a crucial step for induction of heart transplant acceptance under costimulatory blockade. Specialized blood vessels within the LN ...
The final, formatted version of the article will be published soon. Due to their special molecular weight and PK/PD characteristics, antibody drugs are difficult to cross the body barrier and complex ...
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 15, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially ...
AMR is a leading cause of kidney transplant loss with no approved treatments U.S. IND previously approved by FDA for Phase 1 AMR study SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 15, ...
CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with ...
First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework broadens therapeutic opportunities beyond conventional antibodies “We are ...
PLT012 is a first-in-class anti-CD36 monoclonal antibody and the first metabolic checkpoint therapy designed to reprogram the tumor microenvironment Phase 1 trial expected to begin in 1Q 2026 DOVER, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results